Wednesday, September 23 2026

MACTER FY26 profit softens 14%
Macter International Limited (PSX: MACTER) reported a 14% drop in its consolidated net profit for the fiscal year ended June 30, 2026, recording Rs675.17m compared to Rs786.93m in the preceding year. Reflecting this bottom-line compression, basic and diluted earnings per share (EPS) for the year stood at Rs14.83, down from Rs16.95 in FY25. The primary factor weighing on final earnings was higher taxation outlays and selling expense inflation, which offset a strong 17% expansion in top-line revenue. Consolidated revenue from contracts with customers grew by 17% year-on-year to Rs12.17bn, up from Rs10.36bn in FY25. Cost of sales expanded by 11% to Rs6.25bn, allowing gross profit to increase 25% to Rs5.92bn compared to Rs4.73bn in the prior year.
Related news categories: business economic-indicators misc pharma

Friday, September 04 2026

Pakistan pharma industry opposes proposal to alter the drug pricing formula
Pakistan’s pharmaceutical manufacturing industry has expressed concern over a federal minister’s directives to amend the existing drug pricing mechanism, warning that sudden changes could cripple the industry, disrupt medicine supplies and undermine efforts to ensure the availability of affordable medicines. Industry officials said the existing Drug Pricing Policy, 2018 was endorsed by the Supreme Court and was developed by the government through a thorough process involving consultations with stakeholders, rather than by any individual or small group.
Related news categories: business economic-indicators misc pharma

Friday, August 28 2026

ABOT 1HCY26 profit rises 17%
Abbott Laboratories (Pakistan) Limited (PSX: ABOT) reported a 17% increase in its net profit for the half-year ended June 30, 2026 (1HCY26), reaching Rs4.14bn compared to Rs3.54bn in the corresponding period last year. Reflecting this solid bottom-line growth, basic and diluted earnings per share (EPS) for the six-month period improved to Rs42.29, up from Rs36.19 in 1HCY25. The primary catalyst behind the financial expansion was a combination of steady local revenue growth and expanded gross margins. Net sales grew by 4% year-on-year to Rs38.03bn, up from Rs36.41bn in 1HCY25, as a 6% increase in local sales (Rs37.15bn) offset a 41% decline in export sales (Rs875.69m). Meanwhile, the cost of sales decreased slightly by 1% to Rs23.58bn, enabling gross profit to expand 15% to Rs14.45bn compared to Rs12.61bn in the prior year.
Related news categories: business economic-indicators pharma psx stock-exchanges
Related symbols: abot (news stock)